Previous 10 | Next 10 |
ISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russ...
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrate...
ISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. ...
Outlook Therapeutics (NASDAQ:OTLK): FY GAAP EPS of -$0.35 in-line. At September 30, 2021, Outlook Therapeutics had cash and cash equivalents of $14.5M. Press Release For further details see: Outlook Therapeutics EPS in-line
Positive clinical data reported for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in 2021 from multiple clinical trials, including statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial for wet age-related macular degeneration (wet AMD) ...
ISELIN, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Francesco...
ISELIN, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Suber Hua...
Outlook Therapeutics (NASDAQ:OTLK) moves up after the company disclosed a series of insider buying actions coming in from C-level executives. The SEC Filing shows CEO and President C.Russell Trenary III has bought 25,000 shares at a price of $1.39 each. The move takes the Trenary direct benef...
Insiders Decided These Were Peny Stocks To Buy Right Now Do you like taking advantage of discounts? Whether it’s something you saw online or a clearance sale at a local store, everyone wants a deal. Taking advantage of perceived value at lower prices is engrained in the fabric of...
Penny Stocks To Buy For Under $5; Are They Worth The Risk? There are so many traders in the stock market today searching for top penny stocks to buy. These high-risk assets have been a source for some of the biggest winning trades over the last few years. I’m not only talking abo...
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Website:
2024-07-16 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...